ELISA/assay

Monkey Plasminogen ELISA Kit

MBS046502

48-Strip-Wells

435 USD

ELISA Kit

Monkey Plasminogen ELISA Kit

Plasminogen

plasminogen; Plasminogen; plasminogen; plasminogen

PLG

PLG; PLG

PLMN_HUMAN

Monkey

No significant cross-reactivity or interference between Monkey PLG and analogues was observed.

Store all reagents at 2-8 degree C

Samples: Serum, Plasma, Tissue Homogenate, Feces, Urine and Body Fluids. Assay Type: Sandwich. Detection Range: 25 ug/ml - 800 ug/ml. Sensitivity: 2.0 ug/ml.

Intended Uses: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated PLG concentrations in Monkey serum, plasma and other body fluids. Using Purified Monkey PLG antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add PLG and PLG antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of PLG in the samples is then determined by comparing the O.D. of the samples to the standard curve. Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean x100]

Background/Introduction: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated PLG concentrations in Monkey serum, plasma and other body fluids. Using Purified Monkey PLG antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add PLG and PLG antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of PLG in the samples is then determined by comparing the O.D. of the samples to the standard curve.

190026

AAA36451.1

P00747

90,569 Da

Activation Of Matrix Metalloproteinases Pathway (576264); Angiopoietin Receptor Tie2-mediated Signaling Pathway (137917); Blood Clotting Cascade Pathway (198840); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Degradation Of The Extracellular Matrix Pathway (576263); Dissolution Of Fibrin Clot Pathway (106061); Extracellular Matrix Organization Pathway (576262); Hemostasis Pathway (106028)

The protein encoded by this gene is a secreted blood zymogen that is activated by proteolysis and converted to plasmin and angiostatin. Plasmin dissolves fibrin in blood clots and is an important protease in many other cellular processes while angiostatin inhibits angiogenesis. Defects in this gene are likely a cause of thrombophilia and ligneous conjunctivitis. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Dec 2009]

Plasminogen: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Defects in PLG are the cause of plasminogen deficiency (PLGD). PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. Belongs to the peptidase S1 family. Plasminogen subfamily. Protein type: Secreted; Protease; EC 3.4.21.7; Motility/polarity/chemotaxis; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 6q26. Cellular Component: extracellular space; cell surface; extrinsic to external side of plasma membrane; extracellular region; plasma membrane. Molecular Function: protein domain specific binding; protein binding; serine-type peptidase activity; serine-type endopeptidase activity; apolipoprotein binding; receptor binding. Biological Process: platelet activation; extracellular matrix organization and biogenesis; tissue remodeling; muscle maintenance; myoblast differentiation; negative regulation of cell proliferation; extracellular matrix disassembly; fibrinolysis; negative regulation of fibrinolysis; platelet degranulation; cellular protein metabolic process; proteolysis involved in cellular protein catabolic process; tissue regeneration; positive regulation of fibrinolysis; blood coagulation; transmembrane transport. Disease: Plasminogen Deficiency, Type I

48-Strip-Wells

435 USD

96-Strip-Wells

600